Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia
Metlay, JP et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and the Infectious Diseases Society of America. Am. J. Breathe. Critical. Med Care. 200e45-e67 (2019).
Pragman, AA, Berger, JP & Williams, BJ Understanding persistent bacterial lung infections: clinical implications informed by microbiota and biofilm biology. Clin. Pulme. Med. 2357-66 (2016).
Mettelman, RC, Allen, EK & Thomas, PG Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55749-780 (2022).
Hewitt, RJ & Lloyd, CM Regulation of immune responses by the airway epithelial cellular landscape. Nat. Reverend Immunol. 21347-362 (2021).
Cookson, WO, Cox, MJ and Moffatt, MF New opportunities for managing acute and chronic lung infections. Nat. Reverend Microbiol. 16111-120 (2018).
Parmanik, A. et al. Current treatment strategies against multidrug-resistant bacteria: a review. Curr. Microbiol. 79388 (2022).
Grief, SN & Loza, JK Guidelines for the assessment and treatment of pneumonia. Prim. Care: Clin. Disabled. Practice. 45485-503 (2018).
Kellum, JA et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results from the Genetic and Inflammatory Markers of Sepsis Study (GenIMS). Camber. Internal. Med. 1671655-1663 (2007).
Kumar, V. The pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. In front. Immunol. 111722 (2020).
Mookherjee, N., Anderson, MA, Haagsman, HP & Davidson, DJ Antimicrobial host defense peptides: functions and clinical potential. Nat. Rev. 19311-332 (2020).
Dijksteel, GS, Ulrich, MM, Middelkoop, E. & Boekema, BK Lessons learned from clinical trials using antimicrobial peptides (AMPs). In front. Microbiol. 12616979 (2021).
Izadpanah, A. & Gallo, RL Antimicrobial peptides. Jam. Acad. Dermatol. 52381-390 (2005).
Zhang, L.-j. & Gallo, RL Antimicrobial peptides. Curr. Biol. 26R14 to R19 (2016).
Di, YP, Kuhn, JM & Mangoni, ML Pulmonary antimicrobial proteins and peptides: from host defense to therapeutic strategies. Physiol. Round. 1041643-1677 (2024).
Mahlapuu, M., Björn, C. & Ekblom, J. Antimicrobial peptides as therapeutic agents: opportunities and challenges. Critical. Reverend Biotechnology. 40978-992 (2020).
Hou, X. et al. Vitamin and lipid nanoparticles enable adoptive transfer of macrophages for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnology. 1541-46 (2020).
Steinstraesser, L. et al. Skin electroporation of a plasmid encoding the host defense peptide hCAP-18/LL-37 promotes wound healing. Mol. There. 22734-742 (2014).
Pyzik, M., Kozicky, LK, Gandhi, AK & Blumberg, RS The therapeutic age of the neonatal Fc receptor. Nat. Reverend Immunol. 23415-432 (2023).
Czajkowsky, DM, Hu, J., Shao, Z. & Pleass, RJ Fc fusion proteins: new developments and future perspectives. EMBO Mol. Med. 41015-1028 (2012).
Levin, D., Golding, B., Strome, SE & Sauna, ZE Fc fusion as a technology platform: potential for modulating immunogenicity. Biotechnology Trends. 3327-34 (2015).
Dürr, UH, Sudheendra, US and Ramamoorthy, A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochemistry. Biophysics. Acta 17581408-1425 (2006).
Sørensen, OE et al. The human cathelicidin, hCAP-18, is transformed into the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 973951-3959 (2001).
Park, MD, Silvin, A., Ginhoux, F. and Merad, M. Macrophages in health and disease. Cell 1854259-4279 (2022).
Rosales, C. & Uribe-Querol, E. Phagocytosis: a fundamental process of immunity. BioMed. Res. Int. 20179042851 (2017).
Nimmerjahn, F. & Ravetch, JV Fcγ receptors as regulators of immune responses. Nat. Reverend Immunol. 834-47 (2008).
Uribe-Querol, E. & Rosales, C. Phagocytosis: our current understanding of a universal biological process. In front. Immunol. 111066 (2020).
Herrero-Cervera, A., Soehnlein, O. & Kenne, E. Neutrophils in chronic inflammatory diseases. Cell. Mol. Immunol. 19177-191 (2022).
Mittal, M., Siddiqui, MR, Tran, K., Reddy, SP and Malik, AB Reactive oxygen species in inflammation and tissue damage. Antioxidant. Redox signal. 201126-1167 (2014).
Saxton, RA, Glassman, CR & Garcia, KC Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. 2221-37 (2023).
Huang, X., He, D., Pan, Z., Luo, G. and Deng, J. Reactive oxygen species scavenging nanomaterials for resolving inflammation. Master. Today’s biography 11100124 (2021).
Wang, S. et al. Acceleration of diabetic wound healing thanks to a formulation of lipid nanoparticles and mRNA eliminating ROS. Proc. Natl Acad. Sci. USA 121e2322935121 (2024).
Zhang, F. et al. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat. Master. 211324-1332 (2022).
Macia, MD et al. Efficacy and resistance selection potential of antipseudomonas treatments in a mouse model of hypermutable lung infection Pseudomonas aeruginous. Antimicrobial. Agents Chemother. 50975-983 (2006).
Lee, AS et al. Methicillin resistant Staphylococcus aureus. Nat. Reverend Dis. Prim. 418033 (2018).
Zeng, C. et al. Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Av. Maître. 322004452 (2020).
Chen, R. et al. Circular RNA engineering for enhanced protein production. Nat. Biotechnology. 41262-272 (2023).
Wang, C. et al. Lipid nanoparticles crossing the blood-brain barrier for mRNA delivery to the central nervous system. Nat. Master. 241653-1663 (2025).
Kim, M. et al. Dual LNP SORT for multi-organ base editing. Nat. Biotechnology. https://doi.org/10.1038/s41587-025-02675-z (2025).
Devkota, SP, Onah, C., Joshi, PR, Adhikari, S. & Baral, P. Optimized method for higher yield of alveolar macrophage isolation for ex vivo studies. Heliyon 10e37221 (2024).
Xue, Y. et al. LNP-RNA-mediated antigen presentation exploits SARS-CoV-2-specific immunity for cancer treatment. Nat. Common. 162198 (2025).
Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Prim. 363 (2023).
Mukherjee, A. et al. Mutant α-ENaC subunit mRNA, delivered by lipid nanoparticles, reduces amiloride currents in cystic fibrosis-based cell and mouse models. Sci. Av. 6eabc5911 (2020).
Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for lung gene therapy. Nat. Biotechnology. https://doi.org/10.1038/s41587-024-02490-y (2024).
Kim, J. et al. Engineering of lipid nanoparticles to improve intracellular delivery of mRNA by inhalation. ACS Nano 1614792-14806 (2022).
Sun, Y. et al. In vivo editing of lung stem cells for lasting genetic correction in mice. Science 3841196-1202 (2024).
Facchini, M., De Fino, I., Riva, C. and Bragonzi, A. Long-term chronicle Pseudomonas aeruginosa respiratory tract infection in mice. J. Vis. Exp. 8551019 (2014).
Google Scholar
van den Berg, E. et al. Role of the Fas/FasL system in a model of RSV infection in mechanically ventilated mice. Am. J. Physiol. Lung cell. Mol. Physiol. 301L451-L460 (2011).
